SKLB-163 MedChemExpress (MCE)

Product Name	N-Benzyl-2-[6-(2-chloroacetylamino)-benzothiazol-2-ylsulfanyl]-acetamide
Synonyms	N-Benzyl-2-[6-(2-chloroacetylamino)-benzothiazol-2-ylsulfanyl]-acetamide;SKLB 163;SKLB163;SKLB-163;Acetamide, 2-[[6-[(2-chloroacetyl)amino]-2-benzothiazolyl]thio]-N-(phenylmethyl)-;CHEMBL1668233
CAS	1255099-06-9
EINECS
Chemical Formula	C18H16ClN3O2S2
Molecular Weight	405.92
inchi
Package	1 mg;5 mg
Price	Email to quote
Descriptions	SKLB-163 SKLB-163 MedChemExpress (MCE) HY-120429 1255099-06-9 Please store the product under the recommended conditions in the Certificate of Analysis. Room temperature in continental US Descriptions SKLB-163 SKLB-163 MedChemExpress (MCE) HY-120429 1255099-06-9 Please store the product under the recommended conditions in the Certificate of Analysis. Room temperature in continental US may vary elsewhere. SKLB-163 is an orally active inhibitor for Rho GDP-dissociation (RhoGDI). SKLB-163 inhibits highly expressed RhoGDI tumor cell proliferation and migration, and increases radiosensitivity of tumor cells. SKLB-163 induces cancer cell Apoptosis. SKLB-163 (0-20 μM, 48 h) inhibits proliferation and migration of nasopharyngeal carcinoma (NPC) cells, and sensitizes cells to irradiation[1]. SKLB-163 (0-20 μM, 48 h) shows cytotoxicity effect in A375, SPC-A1, SW620, HeLa, PC-3 cells[2]. SKLB-163 (0-2.5 μM, 48 h) induces A375 cell apoptosis and inhibits colony information[2]. SKLB-163 (25-100 mg/kg, i.g., once daily for 30 days) inhibits tumor growth and ascites formation, and inhibits liver and lung metastasis in NPC lung metastatic mice model[1]. SKLB-163 (50 mg/kg, once daily. from the 6th day of SKLB-163 administration, 3 Gy radiation once per day for 3 days) sensitizes NPC tumor to irradiation in CNE-2 and C666-1 subcutaneous xenograft mice models[1]. \| \| \| \| \| \| \| \| \| \| [1]. He J, et al. Antitumor and radiosensitizing effects of SKLB-163, a novel benzothiazole-2-thiol derivative, on nasopharyngeal carcinoma by affecting the RhoGDI/JNK-1 signaling pathway. Radiother Oncol. 2018 Oct 129(1):30-37. [Content Brief] [2]. Peng X,et al. SKLB-163, a new benzothiazole-2-thiol derivative, exhibits potent anticancer activity by affecting RhoGDI/JNK-1 signaling pathway. Cell Death Dis. 2014 Mar 27 5(3):e1143. [Content Brief]
Supplier Website	https://www.medchemexpress.com/sklb-163.html
Last Update	2025-05-21 16:50:25

MedChemExpress (MCE) also provides

Thalidomide-4-O-C2-NH2

Category: Signaling Pathways
CAS: 2341840-99-9
Last Update: 2025-05-21 16:50:25

PPARα-MO-1

Category: Signaling Pathways
CAS: 810677-36-2
Last Update: 2025-05-21 16:50:25

Netupitant N-oxide

Category: Signaling Pathways
CAS: 910808-11-6
Last Update: 2025-05-21 16:50:25

MK-0812

Category: Signaling Pathways
CAS: 624733-88-6
Last Update: 2025-05-21 16:50:25

TS-011

Category: Signaling Pathways
CAS: 339071-18-0
Last Update: 2025-05-21 16:50:25

SCH 530348 sulfate

Category: Signaling Pathways
CAS: 705260-08-8
Last Update: 2025-05-21 16:50:25

BAG 956

Category: Signaling Pathways
CAS: 853910-02-8
Last Update: 2025-05-21 16:50:25

YM758

Category: Signaling Pathways
CAS: 312752-85-5
Last Update: 2025-05-21 16:50:25


Supplier Name	MedChemExpress (MCE)
Contact	sales
Tel	609-228-6898
Mobile	609-228-6898
QQ
Email	sales@medchemexpress.com; tech@medchemexpress.com
Website	https://www.medchemexpress.com/
Wechat

Request for quotation

Supplier Contact